

TCTAP 2023

Coronary CT angiography for Heart Team Decision-making in Multivessel Coronary Artery Disease

Yoshinobu Onuma, MD, PhD

**Professor in Interventional Cardiology at University of Galway, Medical Director
CORRIB Corelab research centre for coronary imaging and Atherosclerosis research**

Nozomi Kotoku, MD

Patrick W. Serruys, MD, PhD

Monday, May 8

7:16 am-7:23 am

Coronary Theater, Walker Hall, Level 1

Disclosure

- I have no conflicts of interest

Guideline Recommendations for Coronary CTA

NICE National Institute for Health and Care Excellence

Clinical guideline
Published: 24 March 2010
nice.org.uk/guidance/ce95

guideline

Chest pain of recent onset: assessment and diagnosis

Recommend CTA as first-line test

Using CTA with FFR_{CT} may lead to cost savings of £214 per patient avoiding invasive investigation and treatment (13 Feb 2017).

Projection... ↑
CTA **400%** ↑
Invasive angiography **60%** ↓

Should NICE guidelines be universally accepted for the evaluation of stable coronary disease? A debate

Harvey S. Hecht^{1*}, Leslee Shaw², Y.S. Chandrashekar³, Jeroen J. Bax⁴, and Jagat Narula¹

NICE Guideline: The Scales of CTA Evidence

PRO: Highest sensitivity, Better prognosticator, Improves outcomes & medical Rx

CON: Lower specificity, functional component, Less availability

Balanced

Go to the Best available technology & expertise
Stenosis + Risk + Ischemia

+ FFR_{CT}
+ High risk plaque

In favor of CTA as driven by NICE guidelines

Eur Heart J. 2019 May 7;40(18):1440-1453.

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)

Class I Level B recommendation

Coronary CTA with Non-invasive functional imaging recommended as **the initial test to diagnose CAD** in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone.


Knuuti J, Wijns W, et al. Eur Heart J. 2019 Aug 31. pii: ehz425.

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain


1 **A**

For intermediate-risk patients with acute chest pain and no known CAD eligible for diagnostic testing after a negative or inconclusive evaluation for ACS, **CCTA is useful for exclusion of atherosclerotic plaque and obstructive CAD**


The role of CCTA in CAD: a diagnostic tool, decision maker and treatment planner




Treatment Planner



Decision Maker



Coronary Plaque Activity/Risk Assessment



Serruys et al. JACC State-of-the-Art Review CCTA vol.78:713-736.

Serruys et al. State-of-the-art EuroIntervention 2023;18(16):e1307-e1327.

CT-SYNTAX Score

Serruys PW, et al, JACC Cardiovasc Imaging. 2013 Mar;6(3):413-5.


A Feasibility and Reproducibility Study

Segments with disease


3. Specify which segments are diseased for lesion 1. ⓘ

Click on the coronary tree image to select or unselect segments.

| | | (Right dominance) | | Total occlusion: x5 |
|------------------|----------------------------|-------------------|--------------------------|------------------------|
| | | Lesion: | 1 | Significant lesion: x2 |
| <i>Segments:</i> | | | | |
| RCA | RCA proximal | 1 | <input type="checkbox"/> | 1 |
| | RCA mid | 2 | <input type="checkbox"/> | 1 |
| | RCA distal | 3 | <input type="checkbox"/> | 1 |
| LM | Left main | 5 | <input type="checkbox"/> | 5 |
| LAD | LAD proximal | 6 | <input type="checkbox"/> | 3.5 |
| | LAD mid | 7 | <input type="checkbox"/> | 2.5 |
| | LAD apical | 8 | <input type="checkbox"/> | 1 |
| | First diagonal | 9 | <input type="checkbox"/> | 1 |
| | Add. first diagonal | 9a | <input type="checkbox"/> | 1 |
| | Second diagonal | 10 | <input type="checkbox"/> | 0.5 |
| | Add. second diagonal | 10a | <input type="checkbox"/> | 0.5 |
| LCX | Proximal circumflex | 11 | <input type="checkbox"/> | 1.5 |
| | Intermediate/anterolateral | 12 | <input type="checkbox"/> | 1 |
| | Obtuse marginal | 12a | <input type="checkbox"/> | 1 |
| | Obtuse marginal | 12b | <input type="checkbox"/> | 1 |
| | Distal circumflex | 13 | <input type="checkbox"/> | 0.5 |
| | Left posterolateral | 14 | <input type="checkbox"/> | 0.5 |
| | Left posterolateral | 14a | <input type="checkbox"/> | 0.5 |
| | Left posterolateral | 14b | <input type="checkbox"/> | 0.5 |
| | Posterior descending | 15 | <input type="checkbox"/> | n.a. |



Anatomic calculation of >50% stenosis






Functional calculation stenosis with <0.80 FFR

Length of lesion



The length of a stenosis can be calculated from the 3D model.

length of >20mm).




Extent of calcification

Calcified plaque is detected and classified in the 3D model.




Cubic mm, circular

Tortuosity (index of curvature)



Max curvature: 0.57(1/mm)
Window size: 3.0 [mm]




Diffuse disease(75% < 2mm)

The size and length of every vessel is quantified in the 3D model.



Less than 2 mm



Recommendation for the revascularization mode in patients with multivessel disease

ESC Guideline 2018

Neumann FJ et al. Eur Heart J. 2019 Jan 7;40(2):87-165.

Pts without DM

Pts with DM

| Extent of CAD | CABG | | PCI | | Extent of CAD | CABG | | PCI | |
|--|-------|-------|-------|-------|--|-------|-------|-------|-------|
| | Class | Level | Class | Level | | Class | Level | Class | Level |
| 3VD with low SS (0-22) | I | A | I | A | 3VD with low SS (0-22) | I | A | IIb | A |
| 3VD with intermediate or high SS (>22) | I | A | III | A | 3VD with intermediate or high SS (>22) | I | A | III | A |

ACC/AHA/SCAI Guideline 2021

Jennifer S. Lawton et al. Circulation. 2021;144:00-00.

Recommendations for Revascularization to Improve Survival in SIHD Compared With Medical Therapy

| | CABG | | PCI | |
|--|--|--|---|--|
| Left ventricular dysfunction and multivessel CAD | I | | B-R | |
| Multivessel CAD | IIb | | IIb | |
| | In patients with SIHD, normal ejection fraction, significant stenosis in 3 major coronary arteries, and anatomy suitable for CABG, CABG may be reasonable to improve survival. | | In patients with SIHD, normal ejection fraction, significant stenosis in 3 major coronary arteries, and anatomy suitable for PCI, the usefulness of PCI to improve survival is uncertain. | |

Recommendation for the revascularization mode in patients with left main disease

ESC Guideline 2018

Neumann FJ et al. Eur Heart J. 2019 Jan 7;40(2):87-165.

| Extent of CAD | CABG | | PCI | |
|--|------|---|-----|---|
| Left main disease with low SS (0-22) | I | A | I | A |
| Left main disease with intermediate SS (23-32) | I | A | IIa | A |
| Left main disease with high SS (≥ 33) | I | A | III | B |

ACC/AHA/SCAI Guideline 2021

Jennifer S. Lawton et al. Circulation. 2021;144:00-00.

Recommendations for Revascularization to Improve Survival in SIHD Compared With Medical Therapy


| | CABG | | PCI | |
|---------------|--|-----|---|------|
| Left main CAD | I | B-R | IIa | B-NR |
| | In patients with SIHD and significant left main stenosis, CABG is recommended to improve survival. | | In selected patients with SIHD and significant LM stenosis for whom PCI can provide equivalent revascularization compared with CABG, PCI is reasonable to improve survival. | |





Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease

Carlos Collet^{1,2†}, Yoshinobu Onuma^{3,4†}, Daniele Andreini⁵, Jeroen Sonck², Giulio Pompilio⁵, Saima Mushtaq⁵, Mark La Meir⁶, Yosuke Miyazaki³, Johan de Mey⁷, Oliver Gaemperli⁶, Ahmed Ouda⁸, Juan Pablo Maureira⁹, Damien Mandry¹⁰, Edoardo Camenzind¹¹, Laurent Macron¹², Torsten Doenst¹³, Ulf Teichgräber¹⁴, Holger Sigusch¹⁵, Taku Asano¹, Yuki Katagiri¹, Marie-angele Morel³, Wietze Lindeboom⁴, Gianluca Pontone⁵, Thomas F. Lüscher^{8,16}, Antonio L. Bartorelli^{5,17*}, and Patrick W. Serruys^{16*};
for the SYNTAX III REVOLUTION investigators

CCTA combined with FFR_{CT} for Heart Team Decision-making in Multivessel Coronary Disease

*Randomizing doctors and not the patient!
In a virtual trial*






| | Heart team treatment recommendation based on coronary computed tomography angiography | | |
|---|---|----------------------------|-----------------|
| Heart team treatment recommendation based on conventional angiography | CABG | PCI/Equipoise CABG and PCI | |
| CABG | 23.4% (52/222) | 2.7% (6/222) | 26.1% (58/222) |
| PCI/Equipoise CABG and PCI | 4.5% (10/222) | 69.4% (154/222) | 73.9% (164/222) |
| | 27.9% (62/222) | 72.1 (160/222) | 92.8%(206/222) |
| Cohen's kappa 0.82 (95% CI 0.73 to 0.91) | | | |

- The heart team **changed the treatment recommendation in 7%** of the cases and modified the selection of **vessel to be revascularization in 12%** when **functional evaluation with FFR_{CT}** was added to an anatomical assessment with CCTA.

- **SYNYAX III demonstrated that CT could be used for decision-making of the selection of revascularization mode between CABG or PCI.**
- **The question remains whether surgeons can operate CABG solely based on CCTA?**

FASTTRACK CABG Trial

CABG plan in "CCTA Planning and Operating Heart Team"




The FASTTRACK CABG study evaluates the **feasibility and safety of planning and execution of CABG solely based on CCTA combined with FFR_{CT}** without knowledge of the anatomy defined by invasive coronary angiography. At 30 days after CABG, postsurgical CCTA is performed to evaluate the patency of bypass grafts.

CABG Planning solely based on CCTA combined with FFR_{CT}

The real thing
has started!
Ongoing trial

FASTTRACK CABG trial

Kawashima, Onuma, Serruys et al.
BMJ2020;10:e038152.



- Segment 1
Total: 2 pts


- Segment 2
Total: 2 pts

- Segment 3
Total: 2 pts

- Segment 5,6,7,11,12,12a
- Trifurcation (1,1,1,1) (seg. 5,6,7,12)
- TO (segment 7), Side branch ≥ 1.5 mm (Seg.9)
- Heavy calcification
Total: 46.5 pts








- Segment 12 (IM)
- Segment 12
Total: 4 pts

- Segment 12a
Total: 2 pts




**Total anatomic SYNTAX score:
58.5 pts**


Pre CABG FFR_{CT}



SYNTAX Score 2020 Predicts 5-year MACE and 10-year mortality





- **Anatomical SYNTAX score**
58.5
- **Age (years)**
81
- **CrCl (ml/min)**
71.0
- **LVEF**
65.0%
- **Left main disease**
Yes
- **Gender**
Male
- **COPD**
No
- **Peripheral vessel disease**
No
- **DM**
No
- **Current Smoking**
No



CABG plan in "CCTA Planning and Operating Heart Team"




Actual treatment of CABG



Hologram post-CABG




Post CABG FFR_{CT} 30 days safety assessment



Enrolment is almost completed
Sample size = 114 patients

LMCAD 16%

Cumulative enrolment of FASTTRACK CABG




In Galway, we have entered into the era of Mixed Reality: "Heart team new style"...with Hologram



Heart Team



**Surgeon on his way to
operator room**



Surgery theatre



OLLSCOIL NA GAILLIMHÉ
UNIVERSITY OF GALWAY





Conclusion

- **In the 2019 ESC guidelines, CCTA with non-invasive functional imaging was given a Class I Level B recommendation as the initial test to diagnose CAD in symptomatic patients.**
- **In complex CAD, CCTA can evaluate the total burden and severity of coronary artery disease (e.g., SYNTAX Score, Leaman Score).**
- **CCTA could be used as a “one-stop shop” diagnostic tool and decision-making between pharmacological treatment, PCI, and CABG.**
- **SYNTAX III REVOLUTION trial demonstrated that clinical decision-making between CABG and PCI based on CCTA had a high agreement with the treatment decision derived from ICA in patients with 3VD with or without left main disease.**
- **The ongoing FASTTRACK CABG trial investigates the feasibility and the safety of planning and executing CABG based solely on CCTA combined with FFR_{CT} without knowledge of anatomy defined by ICA.**